Table 1.
Baseline characteristics
| Characteristics | 280 mg/m2/4 hours | 380 mg/m2/4 hours | All patients | ||
| (n=6) | (n=1) | (n=7) | |||
| Age (years) | 68 (52–73) | 70 | 68 (52–73) | ||
| Sex | |||||
| Female | 4 (66.7%) | 0 | 4 (57.1%) | ||
| Race | |||||
| Asian | 6 (100%) | 1 (100%) | 7 (100%) | ||
| White | 0 | 0 | 0 | ||
| Other | 0 | 0 | 0 | ||
| Treatment | |||||
| Ursodeoxycholic acid | |||||
| Use at baseline | 6 (100%) | 1 (100%) | 7 (100%) | ||
| Daily dose (mg) | |||||
| 600 | 3 (50%) | 1 (100%) | 4 (57%) | ||
| 900 | 3 (50%) | 0 | 3 (43%) | ||
| Fibrate | |||||
| Use at baseline | 2 (33%) | 0 | 2 (29%) | ||
| Laboratory data | Upper Limit of Normal | ||||
| Male | Female | ||||
| Total bilirubin (mg/dL) | 1.5 | 1.5 | 0.9 (0.5–3.9) | 0.9 | 0.9 (0.5–3.9) |
| ALT (U/L) | 42 | 23 | 30 (17–71) | 37 | 33 (17–71) |
| AST (U/L) | 30 | 30 | 40 (23–88) | 41 | 41 (23–88) |
| ALP (U/L) | 322 | 322 | 253 (139–948) | 297 | 283 (139–948) |
| γ-GTP (U/L) | 64 | 32 | 42 (13–210) | 57 | 57 (13–210) |
| Alb (g/dL) | 5.1 | 5.1 | 3.6 (2.9–4.2) | 4 | 3.6 (2.9–4.2) |
| PT (%) | 130 | 130 | 87 (55–100) | 95 | 90 (55–100) |
| PLT count (109/L) | 348 | 348 | 111 (47–181) | 89 | 104 (47–181) |
| Total cholesterol (mg/dL) | 219 | 219 | 184 (142–208) | 240 | 201 (142–240) |
| Fibrosis-related data | |||||
| Liver stiffness (kPa) | 17.0 (6.4–40.3) | 27.4 | 22.3 (6.4–40.3) | ||
| Liver histology | |||||
| Scheuer class | |||||
| III | 3 (50%) | 0 | 3 (43%) | ||
| IV | 3 (50%) | 1 (100%) | 4 (57%) | ||
| Ascites—no (%) | |||||
| None | 4 (67%) | 1 (100%) | 5 (71%) | ||
| Mild or moderate | 2 (33%) | 0 | 2 (29%) | ||
| Severe | 0 | 0 | 0 | ||
| Oesophageal varices | |||||
| None | 4 (67%) | 1 (100%) | 5 (71%) | ||
| (+) | 2 (33%) | 0 | 2 (29%) | ||
Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PLT, Platelet; PT, Prothrombin time; γ-GTP, γ-Glutamyl TransPeptidase.